Drug interactions
Selegiline transdermal + Umeclidinium-vilanterol
Severity: Major
Selegiline transdermal and Umeclidinium-vilanterol: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
MAO inhibitors can potentiate the cardiovascular effects of beta-2 agonists, producing tachycardia, palpitations and blood pressure rises. Transdermal selegiline at antidepressant doses acts as a non-selective MAO inhibitor.
What this interaction means in plain words
Selegiline transdermal and Umeclidinium-vilanterol can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
MAO inhibition enhances adrenergic stimulation and potentiates beta-agonist cardiovascular effects.
What to do
Avoid starting vilanterol during or within 2 weeks of stopping selegiline where possible. If necessary, monitor blood pressure, heart rate and ECG closely.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Selegiline transdermal and Umeclidinium-vilanterol, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Umeclidinium-vilanterol
Frequently asked questions
Can I take Selegiline transdermal with Umeclidinium-vilanterol?
MediHelp rates the interaction as major. Selegiline transdermal and Umeclidinium-vilanterol can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. MAO inhibitors can potentiate the cardiovascular effects of beta-2 agonists, producing tachycardia, palpitations and blood pressure rises. Transdermal selegiline at antidepressant doses acts as a non-selective MAO inhibitor.
How serious is the interaction between Selegiline transdermal and Umeclidinium-vilanterol?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting vilanterol during or within 2 weeks of stopping selegiline where possible. If necessary, monitor blood pressure, heart rate and ECG closely.
What other medicines interact with Umeclidinium-vilanterol?
MediHelp also lists interactions of Umeclidinium-vilanterol with, for example, Aclidinium, Amiodarone, Amitriptyline. The full list is on the Umeclidinium-vilanterol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
